The NM_000023.4: c.502G>A variant in SGCA is a missense variant predicted to cause substitution of glycine by arginine at amino acid 168, p.(Gly168Arg). This variant has been detected in at least three individuals with limb-girdle muscular dystrophy, where it was reported in unconfirmed phase with a likely pathogenic variant in two patients (c.241C>T p.(Arg81Cys), 0.25 pts, PMID: 31268554; c.246C>A p.(Ser82Arg), 0.25 pts, GRASP-LGMD Consortium internal data communication) and in unconfirmed phase with a pathogenic variant in the third patient (c.229C>T p.(Arg77Cys), 0.5 pts, PMID: 39678382) (PM3). At least one of these patients displayed progressive limb girdle muscle weakness (PP4; PMID: 39678382). The Grpmax variant allele frequency in gnomAD v4.1.1 is 0.00004605 (2/43432 East Asian alleles), which is less than the LGMD VCEP threshold for PM2_Supporting. In vitro assay in a heterologous cell system has demonstrated that this variant disrupts membrane localization of the sarcoglycan complex (PS3_Moderate, Washington University internal data). The computational predictor REVEL gives a score of 0.548, which is below the threshold of 0.7 (PP3 not met). In summary, this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 2.0.0; 04/29/2026): PM3, PP4, PM2_Supporting, PS3_Moderate.